image
Healthcare - Drug Manufacturers - General - NASDAQ - US
$ 283.61
-4.16 %
$ 152 B
Market Cap
36.17
P/E
1. INTRINSIC VALUE

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.[ Read More ]

The intrinsic value of one AMGN stock under the base case scenario is HIDDEN Compared to the current market price of 284 USD, Amgen Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart AMGN

image
FINANCIALS
28.2 B REVENUE
7.09%
7.9 B OPERATING INCOME
48.02%
6.72 B NET INCOME
2.52%
8.47 B OPERATING CASH FLOW
-12.86%
-26.2 B INVESTING CASH FLOW
-333.55%
21 B FINANCING CASH FLOW
621.38%
8.5 B REVENUE
2.04%
2.05 B OPERATING INCOME
10.41%
2.83 B NET INCOME
279.36%
3.57 B OPERATING CASH FLOW
45.22%
-210 M INVESTING CASH FLOW
3.23%
-3.65 B FINANCING CASH FLOW
-37.83%
Balance Sheet Decomposition Amgen Inc.
image
Current Assets 30.3 B
Cash & Short-Term Investments 10.9 B
Receivables 7.94 B
Other Current Assets 11.4 B
Non-Current Assets 66.8 B
Long-Term Investments 0
PP&E 6.59 B
Other Non-Current Assets 60.2 B
Current Liabilities 18.4 B
Accounts Payable 1.59 B
Short-Term Debt 1.56 B
Other Current Liabilities 15.2 B
Non-Current Liabilities 72.5 B
Long-Term Debt 63.9 B
Other Non-Current Liabilities 8.67 B
EFFICIENCY
Earnings Waterfall Amgen Inc.
image
Revenue 28.2 B
Cost Of Revenue 8.45 B
Gross Profit 19.7 B
Operating Expenses 11.9 B
Operating Income 7.9 B
Other Expenses 1.18 B
Net Income 6.72 B
RATIOS
70.02% GROSS MARGIN
70.02%
28.01% OPERATING MARGIN
28.01%
23.83% NET MARGIN
23.83%
107.78% ROE
107.78%
6.91% ROA
6.91%
9.53% ROIC
9.53%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Amgen Inc.
image
Net Income 6.72 B
Depreciation & Amortization 4.07 B
Capital Expenditures -1.11 B
Stock-Based Compensation 431 M
Change in Working Capital -484 M
Others -1.56 B
Free Cash Flow 7.36 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Amgen Inc.
image
Wall Street analysts predict an average 1-year price target for AMGN of $327 , with forecasts ranging from a low of $215 to a high of $405 .
AMGN Lowest Price Target Wall Street Target
215 USD -24.19%
AMGN Average Price Target Wall Street Target
327 USD 15.30%
AMGN Highest Price Target Wall Street Target
405 USD 42.80%
4. DIVIDEND ANALYSIS
0.70% DIVIDEND YIELD
2.25 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Amgen Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
663 K USD 1
9-12 MONTHS
572 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
6 months ago
May 03, 2024
Sell 663 K USD
Grygiel Nancy A.
SVP & CCO
- 2117
313.0853 USD
11 months ago
Dec 04, 2023
Sell 572 K USD
Grygiel Nancy A.
SVP & CCO
- 2096
273.0323 USD
1 year ago
Nov 08, 2023
Sell 2.73 M USD
Graham Jonathan P
EVP, Gen. Counsel & Secy.
- 10000
272.8136 USD
1 year ago
Aug 10, 2023
Sell 2.51 M USD
Gordon Murdo
EVP, Global Commercial Ops
- 9558
262.43 USD
2 years ago
Nov 09, 2022
Sell 113 K USD
Khosla Rachna
SVP, Business Development
- 387
292.9 USD
2 years ago
Nov 08, 2022
Sell 160 K USD
Grygiel Nancy A.
SVP & CCO
- 545
293.535 USD
2 years ago
Aug 22, 2022
Sell 50 K USD
Williams R Sanders
director:
- 200
249.96 USD
2 years ago
Aug 18, 2022
Sell 1.64 M USD
ECKERT ROBERT
director:
- 6600
248.9966 USD
2 years ago
May 23, 2022
Sell 150 K USD
Williams R Sanders
director:
- 600
250 USD
2 years ago
May 10, 2022
Sell 3.26 M USD
Graham Jonathan P
EVP, Gen. Counsel & Secy.
- 13500
241.8114 USD
3 years ago
May 12, 2021
Sell 251 K USD
SUGAR RONALD D
Director
- 1000
250.59 USD
3 years ago
May 11, 2021
Sell 631 K USD
Grygiel Nancy A.
SVP & CCO
- 2500
252.5089 USD
3 years ago
May 07, 2021
Sell 62.9 K USD
Williams R Sanders
Director
- 250
251.78 USD
3 years ago
Apr 14, 2021
Sell 250 K USD
SUGAR RONALD D
Director
- 1000
249.98 USD
3 years ago
Mar 10, 2021
Sell 232 K USD
SUGAR RONALD D
Director
- 1000
231.53 USD
3 years ago
Feb 10, 2021
Sell 238 K USD
SUGAR RONALD D
Director
- 1000
238.4 USD
3 years ago
Feb 08, 2021
Sell 59.5 K USD
Williams R Sanders
Director
- 250
237.99 USD
3 years ago
Feb 04, 2021
Sell 2.63 M USD
Graham Jonathan P
EVP, Gen. Counsel & Secy.
- 11110
236.5099 USD
3 years ago
Jan 13, 2021
Sell 236 K USD
SUGAR RONALD D
Director
- 1000
235.99 USD
4 years ago
Nov 09, 2020
Sell 60.6 K USD
Williams R Sanders
Director
- 250
242.4 USD
4 years ago
Aug 19, 2020
Sell 241 K USD
SUGAR RONALD D
Director
- 1000
241.02 USD
4 years ago
Aug 07, 2020
Sell 60.7 K USD
Williams R Sanders
Director
- 250
242.95 USD
4 years ago
Jul 22, 2020
Sell 260 K USD
SUGAR RONALD D
Director
- 1000
259.79 USD
4 years ago
Jun 17, 2020
Sell 229 K USD
SUGAR RONALD D
Director
- 1000
228.54 USD
4 years ago
May 20, 2020
Sell 229 K USD
SUGAR RONALD D
Director
- 1000
229.27 USD
4 years ago
May 06, 2020
Sell 101 K USD
Williams R Sanders
Director
- 425
237.31 USD
4 years ago
Apr 22, 2020
Sell 233 K USD
SUGAR RONALD D
Director
- 1000
233.35 USD
4 years ago
Feb 06, 2020
Sell 99.3 K USD
Williams R Sanders
Director
- 425
233.72 USD
4 years ago
Feb 06, 2020
Sell 2.13 M USD
Piacquad David
SVP, Business Development
- 9264
229.9308 USD
4 years ago
Nov 25, 2019
Sell 2.05 M USD
Meline David W
EVP & CFO
- 8737
234.36 USD
4 years ago
Nov 22, 2019
Sell 2.07 M USD
Graham Jonathan P
EVP, Gen. Counsel & Secy.
- 9000
230.5374 USD
5 years ago
Nov 06, 2019
Sell 91.6 K USD
Williams R Sanders
Director
- 425
215.45 USD
5 years ago
Nov 06, 2019
Sell 431 K USD
SUGAR RONALD D
Director
- 2000
215.45 USD
5 years ago
Oct 02, 2019
Sell 387 K USD
SUGAR RONALD D
Director
- 2000
193.58 USD
5 years ago
Sep 04, 2019
Sell 413 K USD
SUGAR RONALD D
Director
- 2000
206.7 USD
5 years ago
Aug 30, 2019
Sell 598 K USD
Patton Cynthia M
SVP & CCO
- 2875
208.0672 USD
5 years ago
Aug 30, 2019
Sell 999 K USD
Patton Cynthia M
SVP & CCO
- 4802
208.0672 USD
5 years ago
Aug 07, 2019
Sell 77.8 K USD
Williams R Sanders
Director
- 425
183.04 USD
5 years ago
Aug 07, 2019
Sell 366 K USD
SUGAR RONALD D
Director
- 2000
183.04 USD
7. News
AMGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Amgen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm NEW YORK, Nov. 15, 2024 (GLOBE NEWSWIRE) --  Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Amgen Inc. (NASDAQ: AMGN) on behalf of long-term stockholders following a class action complaint that was filed against Amgen on March 13, 2023 with a Class Period from July 29, 2020 and April 27, 2022. Our investigation concerns whether the board of directors of Amgen have breached their fiduciary duties to the company. globenewswire.com - 1 day ago
Amgen Shrugs Off Bone Density Concerns Related to Obesity Candidate AMGN says there was no connection between the administration of MariTide and bone mineral density changes. zacks.com - 2 days ago
AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024 MITIGATE Phase 3 Study Results Reinforce Promise of UPLIZNA® as the First Potential Treatment tor IgG4-RD Phase 4 AGILE Data Support Shortening KRYSTEXXA® Infusion Time THOUSAND OAKS, Calif. , Nov. 14, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data across its rare disease portfolio and pipeline at the annual American College of Rheumatology (ACR) Convergence 2024 conference in Washington, D.C. prnewswire.com - 2 days ago
2 Dividend Stocks to Buy Hand Over Fist in November These companies have solid businesses and excellent dividend growth track records. fool.com - 2 days ago
Amgen Inc. (AMGN) UBS Global Healthcare Conference (Transcript) Amgen Inc. (NASDAQ:AMGN ) UBS Global Healthcare Conference November 13, 2024 1:15 PM ET Company Participants Peter Griffith - CFO Narimon Honarpour - SVP, Global Development Justin Claeys - VP, IR Conference Call Participants Trung Huynh - UBS Trung Huynh Okay, great. I think that's quarter past. seekingalpha.com - 3 days ago
Amgen initiated with a Neutral at Citi Citi initiated coverage of Amgen with a Neutral rating and $335 price target. The company's growth picture hinges on MariTide clinical success and to a lesser degree, the trajectory for several newer products, the analyst tells investors in a research note. The firm says MariTide likely will need to demonstrate monthly dosing, 15%-20% minimum weight loss, and less than 10% discontinuations along with benign safety, the analyst tells investors in a research note. https://thefly.com - 3 days ago
Signal Says Pharma Stock Selloff Should Be Over Shares of pharmaceutical giant Amgen (AMGN) are attempting to bounce back after suffering a steep drop of 7.1% yesterday, following reports that the company's weight-loss drug, MariTide, triggers a significant loss in bone density. Last seen holding above $300, AMGN could be due for more chart recovery if past is precedent. forbes.com - 3 days ago
Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density On Tuesday, a Cantor analyst wrote that additional data from Amgen's experimental weight loss injection, MariTide, suggests a new potential safety risk tied to the drug. benzinga.com - 3 days ago
Trade Tracker: Joe Terranova sells Amgen and buys XBI Joe Terranova, senior managing director for Virtus Investment Partners, joins CNBC's 'Halftime Report' to discuss his latest portfolio moves. youtube.com - 3 days ago
What's Happening With Amgen Stock? Amgen stock (NASDAQ: AMGN) saw a 7% fall on Tuesday, November 12, after an update on the progress with its weight-loss drug — MariTide. An early-stage trial for the drug showed loss of bone density, which could be a potential safety risk. forbes.com - 3 days ago
Amgen sees no bone safety concerns around experimental obesity drug Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a day after data from an early-stage study dragged its stock 7% lower. reuters.com - 4 days ago
AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATA THOUSAND OAKS, Calif. , Nov. 13, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today issued the following statement on the MariTide (maridebart cafraglutide, formerly AMG 133) Phase 1 data. prnewswire.com - 4 days ago
8. Profile Summary

Amgen Inc. AMGN

image
COUNTRY US
INDUSTRY Drug Manufacturers - General
MARKET CAP $ 152 B
Dividend Yield 0.70%
Description Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Contact One Amgen Center Drive, Thousand Oaks, CA, 91320-1799 https://www.amgen.com
IPO Date June 17, 1983
Employees 26700
Officers Dr. James E. Bradner M.D. Executive Vice President of Research & Development and Chief Scientific Officer Ms. Nancy A. Grygiel Senior Vice President of Worldwide Compliance & Business Ethics and Chief Compliance Officer Mr. Kave Niksefat Senior Vice President of Global Marketing & Access Dr. David M. Reese M.D. Executive Vice President & Chief Technology Officer Justin G. Claeys Vice President of Investor Relations Mr. Esteban Santos Executive Vice President of Operations Mr. Murdo Gordon Executive Vice President of Global Commercial Operations Mr. Matthew C. Busch Chief Accounting Officer & Vice President of Finance Mr. Robert A. Bradway Chairman, Chief Executive Officer & President Mr. Peter H. Griffith Executive Vice President & Chief Financial Officer